Oarsman Capital’s Sanofi SNY Stock Holding History

Oarsman Capital’s Portfolio SNY Stock Details SNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-4,220	Closed	-$205K	–	256
2025 Q4	$205K	Buy	+4,220	New	+$209K	0.03%	230
2025 Q3	–	Sell	-4,220	Closed	-$204K	–	267
2025 Q2	$204K	Buy	4,220 +477	+13%	+$24.4K	0.03%	238
2025 Q1	$208K	Sell	3,743 -549	-13%	-$29.7K	0.04%	220
2024 Q4	$207K	Sell	4,292 -235	-5%	-$11.9K	0.04%	223
2024 Q3	$261K	Buy	+4,527	New	+$244K	0.05%	199

Other funds holding SNY

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.69B AUM

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Oarsman Capital's SNY Position: Q1 2026 in Review

Oarsman Capital sold out of Sanofi (SNY) in Q1 2026, closing a stake of 4,220 shares — an estimated $205K sold.

Oarsman Capital first reported a position in SNY in Q3 2024 and held it in 5 quarters. The position peaked at $261K in Q3 2024. 738 funds tracked by Wall St. Rank hold SNY as of Q1 2026.

Oarsman Capital reported no remaining Sanofi position as of Q1 2026 after selling out during the quarter.
Oarsman Capital sold 4,220 Sanofi shares in Q1 2026, an estimated $205K.
Oarsman Capital first reported a position in Sanofi in Q3 2024 and held it in 5 quarters.
Oarsman Capital's Sanofi position peaked at $261K in Q3 2024.
738 funds tracked by Wall St. Rank held Sanofi as of Q1 2026.

Based on Oarsman Capital's 13F filing for Q1 2026, filed 28 Apr 2026.